You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 19, 2024

IMBRUVICA Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


When do Imbruvica patents expire, and when can generic versions of Imbruvica launch?

Imbruvica is a drug marketed by Pharmacyclics Llc and is included in three NDAs. There are forty-one patents protecting this drug and four Paragraph IV challenges.

This drug has three hundred and seventy-seven patent family members in forty-five countries.

The generic ingredient in IMBRUVICA is ibrutinib. There are sixteen drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the ibrutinib profile page.

DrugPatentWatch® Generic Entry Outlook for Imbruvica

Imbruvica was eligible for patent challenges on November 13, 2017.

There have been twelve patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

There are six tentative approvals for the generic drug (ibrutinib), which indicates the potential for near-term generic launch.

Indicators of Generic Entry

< Available with Subscription >

  Try a Trial

Drug patent expirations by year for IMBRUVICA
Drug Prices for IMBRUVICA

See drug prices for IMBRUVICA

Recent Clinical Trials for IMBRUVICA

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Peter MacCallum Cancer Centre, AustraliaPhase 2
Oncternal Therapeutics, IncPhase 3
Academic and Community Cancer Research UnitedPhase 2

See all IMBRUVICA clinical trials

Pharmacology for IMBRUVICA
Drug ClassKinase Inhibitor
Mechanism of ActionProtein Kinase Inhibitors
Paragraph IV (Patent) Challenges for IMBRUVICA
Tradename Dosage Ingredient Strength NDA ANDAs Submitted Submissiondate
IMBRUVICA Capsules ibrutinib 70 mg 205552 1 2018-12-14
IMBRUVICA Tablets ibrutinib 280 mg and 420 mg 210563 1 2018-12-14
IMBRUVICA Tablets ibrutinib 140 mg and 560 mg 210563 1 2018-11-05
IMBRUVICA Capsules ibrutinib 140 mg 205552 8 2017-11-13

US Patents and Regulatory Information for IMBRUVICA

IMBRUVICA is protected by forty-four US patents and eight FDA Regulatory Exclusivities.

Patents protecting IMBRUVICA

Use of inhibitors of Bruton's tyrosine kinase (Btk)
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial

Pharmaceutical formulations of a bruton's tyrosine kinase inhibitor
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial

Use of inhibitors of Bruton's tyrosine kinase (Btk)
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial

Crystalline forms of a Bruton's tyrosine kinase inhibitor
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial

Crystalline forms of a bruton's tyrosine kinase inhibitor
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial

Pharmaceutical formulations of a Bruton's tyrosine kinase inhibitor
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial

Crystalline forms of a Bruton's tyrosine kinase inhibitor
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial

Crystalline forms of a Bruton's tyrosine kinase inhibitor
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial

Methods of treating and preventing graft versus host disease
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial

Use of inhibitors of bruton's tyrosine kinase (Btk)
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial

Use of inhibitors of bruton's tyrosine kinase (BTK)
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial

Methods of treating and preventing graft versus host disease
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial

Use of inhibitors of Bruton's tyrosine kinase (Btk)
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial

Crystalline forms of a brutons tyrosine kinase inhibitor
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial

Pharmaceutical formulations of a Bruton's tyrosine kinase inhibitor
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial

Crystalline forms of a Bruton's tyrosine kinase inhibitor
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial


Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial
Patented Use: TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA WITH 17P DELETION


Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial
Patented Use: TREATMENT OF SMALL LYMPHOCYTIC LYMPHOMA WITH 17P DELETION


Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial
Patented Use: TREATMENT OF SMALL LYMPHOCYTIC LYMPHOMA


Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial
Patented Use: TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA

Inhibitors of bruton's tyrosine kinase
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial

Inhibitors of bruton's tyrosine kinase
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial

Inhibitors of Bruton's tyrosine kinase
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial

Inhibitors of Bruton's tyrosine kinase
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial

Inhibitors of bruton's tyrosine kinase
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial

Inhibitors of bruton'S tyrosine kinase
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial

Inhibitors of Bruton's tyrosine kinase
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial

Inhibitors of Bruton's tyrosine kinase
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial

Use of inhibitors of bruton's tyrosine kinase (Btk)
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial

Inhibitors of bruton's tyrosine kinase
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial

Inhibitors of Bruton's tyrosine kinase
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial

Inhibitors of Bruton's tyrosine kinase
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial

Use of inhibitors of Bruton's tyrosine kinase (Btk)
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial

Use of inhibitors of Bruton's tyrosine kinase (Btk)
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial

Inhibitors of Bruton's tyrosine kinase
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial

Crystalline forms of a Bruton's tyrosine kinase inhibitor
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial

Crystalline forms of a Bruton's tyrosine kinase inhibitor
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial

Pharmaceutical formulations of a Bruton's tyrosine kinase inhibitor
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial

Crystalline forms of a Bruton's tyrosine kinase inhibitor
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial

Crystalline forms of a bruton's tyrosine kinase inhibitor
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial

Methods of treating and preventing graft versus host disease
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial

Use of inhibitors of bruton's tyrosine kinase (BTK)
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial

Use of inhibitors of bruton's tyrosine kinase (Btk)
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial

Use of inhibitors of bruton'S tyrosine kinase (BTK)
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial

FDA Regulatory Exclusivity protecting IMBRUVICA

TREATMENT OF PEDIATRIC PATIENTS AGE 1 YEAR AND OLDER WITH CHRONIC GRAFT-VERSUS-HOST DISEASE (CGVHD) AFTER FAILURE OF ONE OR MORE LINES OF SYSTEMIC THERAPY
Exclusivity Expiration: ⤷  Try a Trial

FDA HAS NOT RECOGNIZED ORPHAN-DRUG EXCLUSIVITY (ODE) FOR THIS DRUG, BUT IT CONTAINS THE SAME ACTIVE MOIETY OR MOIETIES AS ANOTHER DRUG(S) THAT WAS ELIGIBLE FOR ODE, AND ALSO SHARES ODE-PROTECTED USE(S) OR INDICATION(S) WITH THAT DRUG(S).AN APPLICATION SEEKING APPROVAL FOR THE SAME ACTIVE MOIETY OR MOIETIES, INCLUDING AN ANDA THAT CITES THIS NDA AS ITS BASIS OF SUBMISSION, MAY NOT BE APPROVED FOR SUCH ODE-PROTECTED USE(S) AND INDICATION(S)
Exclusivity Expiration: ⤷  Try a Trial

NEW PATIENT POPULATION
Exclusivity Expiration: ⤷  Try a Trial

PEDIATRIC EXCLUSIVITY
Exclusivity Expiration: ⤷  Try a Trial

PEDIATRIC EXCLUSIVITY
Exclusivity Expiration: ⤷  Try a Trial

TREATMENT OF ADULT PATIENTS WITH CHRONIC GRAFT VERSUS HOST DISEASE (CGVHD)
Exclusivity Expiration: ⤷  Try a Trial

PEDIATRIC EXCLUSIVITY
Exclusivity Expiration: ⤷  Try a Trial

NEW PRODUCT
Exclusivity Expiration: ⤷  Try a Trial

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Pharmacyclics Llc IMBRUVICA ibrutinib CAPSULE;ORAL 205552-001 Nov 13, 2013 RX Yes Yes ⤷  Try a Trial ⤷  Try a Trial Y ⤷  Try a Trial
Pharmacyclics Llc IMBRUVICA ibrutinib TABLET;ORAL 210563-003 Feb 16, 2018 RX Yes Yes ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
Pharmacyclics Llc IMBRUVICA ibrutinib SUSPENSION;ORAL 217003-001 Aug 24, 2022 RX Yes Yes ⤷  Try a Trial ⤷  Try a Trial Y ⤷  Try a Trial
Pharmacyclics Llc IMBRUVICA ibrutinib TABLET;ORAL 210563-004 Feb 16, 2018 DISCN Yes No ⤷  Try a Trial ⤷  Try a Trial Y ⤷  Try a Trial
Pharmacyclics Llc IMBRUVICA ibrutinib CAPSULE;ORAL 205552-002 Dec 20, 2017 RX Yes No ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

EU/EMA Drug Approvals for IMBRUVICA

Company Drugname Inn Product Number / Indication Status Generic Biosimilar Orphan Marketing Authorisation Marketing Refusal
Janssen-Cilag International NV Imbruvica ibrutinib EMEA/H/C/003791
IMBRUVICA as a single agent is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL).IMBRUVICA as a single agent or in combination with rituximab or obinutuzumab or venetoclax is indicated for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (CLL) (see section 5.1).IMBRUVICA as a single agent or in combination with bendamustine and rituximab (BR) is indicated for the treatment of adult patients with CLL who have received at least one prior therapy.IMBRUVICA as a single agent is indicated for the treatment of adult patients with Waldenström’s macroglobulinaemia (WM) who have received at least one prior therapy, or in first line treatment for patients unsuitable for chemo immunotherapy. IMBRUVICA in combination with rituximab is indicated for the treatment of adult patients with WM.
Authorised no no no 2014-10-21
>Company >Drugname >Inn >Product Number / Indication >Status >Generic >Biosimilar >Orphan >Marketing Authorisation >Marketing Refusal

International Patents for IMBRUVICA

When does loss-of-exclusivity occur for IMBRUVICA?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Argentina

Patent: 2844
Estimated Expiration: ⤷  Try a Trial

Patent: 3832
Estimated Expiration: ⤷  Try a Trial

Patent: 8108
Estimated Expiration: ⤷  Try a Trial

Australia

Patent: 13271918
Estimated Expiration: ⤷  Try a Trial

Patent: 16226279
Estimated Expiration: ⤷  Try a Trial

Patent: 16250445
Estimated Expiration: ⤷  Try a Trial

Patent: 18211201
Estimated Expiration: ⤷  Try a Trial

Patent: 18211216
Estimated Expiration: ⤷  Try a Trial

Patent: 20239751
Estimated Expiration: ⤷  Try a Trial

Patent: 21240244
Estimated Expiration: ⤷  Try a Trial

Patent: 23200435
Estimated Expiration: ⤷  Try a Trial

Patent: 23202671
Estimated Expiration: ⤷  Try a Trial

Brazil

Patent: 2014030424
Estimated Expiration: ⤷  Try a Trial

Patent: 2017018931
Estimated Expiration: ⤷  Try a Trial

Canada

Patent: 75986
Estimated Expiration: ⤷  Try a Trial

Patent: 76695
Estimated Expiration: ⤷  Try a Trial

Patent: 91994
Estimated Expiration: ⤷  Try a Trial

Patent: 15208
Estimated Expiration: ⤷  Try a Trial

Patent: 77990
Estimated Expiration: ⤷  Try a Trial

Patent: 77995
Estimated Expiration: ⤷  Try a Trial

Patent: 18491
Estimated Expiration: ⤷  Try a Trial

Chile

Patent: 14003306
Estimated Expiration: ⤷  Try a Trial

Patent: 17000371
Estimated Expiration: ⤷  Try a Trial

Patent: 17003496
Estimated Expiration: ⤷  Try a Trial

China

Patent: 4736178
Estimated Expiration: ⤷  Try a Trial

Patent: 7427498
Estimated Expiration: ⤷  Try a Trial

Patent: 0354132
Estimated Expiration: ⤷  Try a Trial

Colombia

Patent: 40408
Estimated Expiration: ⤷  Try a Trial

Costa Rica

Patent: 140558
Estimated Expiration: ⤷  Try a Trial

Dominican Republic

Patent: 014000274
Estimated Expiration: ⤷  Try a Trial

Patent: 017000152
Estimated Expiration: ⤷  Try a Trial

Patent: 022000096
Estimated Expiration: ⤷  Try a Trial

Ecuador

Patent: 14033163
Estimated Expiration: ⤷  Try a Trial

Patent: 19015794
Estimated Expiration: ⤷  Try a Trial

Eurasian Patent Organization

Patent: 1492082
Estimated Expiration: ⤷  Try a Trial

European Patent Office

Patent: 54859
Estimated Expiration: ⤷  Try a Trial

Patent: 65084
Estimated Expiration: ⤷  Try a Trial

Guatemala

Patent: 1400281
Estimated Expiration: ⤷  Try a Trial

Hong Kong

Patent: 08803
Estimated Expiration: ⤷  Try a Trial

Patent: 49015
Estimated Expiration: ⤷  Try a Trial

Israel

Patent: 5894
Estimated Expiration: ⤷  Try a Trial

Patent: 3995
Estimated Expiration: ⤷  Try a Trial

Patent: 2367
Estimated Expiration: ⤷  Try a Trial

Patent: 3284
Estimated Expiration: ⤷  Try a Trial

Japan

Patent: 36071
Estimated Expiration: ⤷  Try a Trial

Patent: 37086
Estimated Expiration: ⤷  Try a Trial

Patent: 49076
Estimated Expiration: ⤷  Try a Trial

Patent: 15518885
Estimated Expiration: ⤷  Try a Trial

Patent: 18012710
Estimated Expiration: ⤷  Try a Trial

Patent: 18048182
Estimated Expiration: ⤷  Try a Trial

Patent: 18507200
Estimated Expiration: ⤷  Try a Trial

Patent: 19203008
Estimated Expiration: ⤷  Try a Trial

Patent: 20015744
Estimated Expiration: ⤷  Try a Trial

Patent: 21183617
Estimated Expiration: ⤷  Try a Trial

Patent: 21193095
Estimated Expiration: ⤷  Try a Trial

Patent: 22141701
Estimated Expiration: ⤷  Try a Trial

Patent: 23162162
Estimated Expiration: ⤷  Try a Trial

Jordan

Patent: 0200222
Estimated Expiration: ⤷  Try a Trial

Patent: 54
Estimated Expiration: ⤷  Try a Trial

Malaysia

Patent: 7999
Estimated Expiration: ⤷  Try a Trial

Patent: 4911
Estimated Expiration: ⤷  Try a Trial

Mexico

Patent: 8290
Estimated Expiration: ⤷  Try a Trial

Patent: 14014848
Estimated Expiration: ⤷  Try a Trial

Patent: 17011270
Estimated Expiration: ⤷  Try a Trial

Patent: 21012478
Estimated Expiration: ⤷  Try a Trial

Patent: 21015368
Estimated Expiration: ⤷  Try a Trial

Patent: 21015370
Estimated Expiration: ⤷  Try a Trial

Patent: 21015405
Estimated Expiration: ⤷  Try a Trial

Patent: 21015408
Estimated Expiration: ⤷  Try a Trial

Morocco

Patent: 711
Estimated Expiration: ⤷  Try a Trial

Patent: 643
Estimated Expiration: ⤷  Try a Trial

Patent: 654
Estimated Expiration: ⤷  Try a Trial

New Zealand

Patent: 2548
Estimated Expiration: ⤷  Try a Trial

Patent: 3828
Estimated Expiration: ⤷  Try a Trial

Patent: 1932
Estimated Expiration: ⤷  Try a Trial

Patent: 4446
Estimated Expiration: ⤷  Try a Trial

Patent: 7725
Estimated Expiration: ⤷  Try a Trial

Peru

Patent: 150174
Estimated Expiration: ⤷  Try a Trial

Patent: 190390
Estimated Expiration: ⤷  Try a Trial

Philippines

Patent: 014502681
Estimated Expiration: ⤷  Try a Trial

Patent: 020500028
Estimated Expiration: ⤷  Try a Trial

Russian Federation

Patent: 17133990
Estimated Expiration: ⤷  Try a Trial

Singapore

Patent: 202101389T
Estimated Expiration: ⤷  Try a Trial

Patent: 202102078V
Estimated Expiration: ⤷  Try a Trial

Patent: 201408067Y
Estimated Expiration: ⤷  Try a Trial

Patent: 201707122Q
Estimated Expiration: ⤷  Try a Trial

South Africa

Patent: 1907661
Estimated Expiration: ⤷  Try a Trial

Patent: 2105174
Estimated Expiration: ⤷  Try a Trial

Patent: 2105175
Estimated Expiration: ⤷  Try a Trial

South Korea

Patent: 150015021
Estimated Expiration: ⤷  Try a Trial

Patent: 170091785
Estimated Expiration: ⤷  Try a Trial

Patent: 170122220
Estimated Expiration: ⤷  Try a Trial

Patent: 190040370
Estimated Expiration: ⤷  Try a Trial

Patent: 200017549
Estimated Expiration: ⤷  Try a Trial

Patent: 210033067
Estimated Expiration: ⤷  Try a Trial

Patent: 220093389
Estimated Expiration: ⤷  Try a Trial

Patent: 230170108
Estimated Expiration: ⤷  Try a Trial

Taiwan

Patent: 32912
Estimated Expiration: ⤷  Try a Trial

Patent: 53041
Estimated Expiration: ⤷  Try a Trial

Patent: 62963
Estimated Expiration: ⤷  Try a Trial

Patent: 62964
Estimated Expiration: ⤷  Try a Trial

Patent: 33027
Estimated Expiration: ⤷  Try a Trial

Patent: 10588
Estimated Expiration: ⤷  Try a Trial

Patent: 1402122
Estimated Expiration: ⤷  Try a Trial

Patent: 1636023
Estimated Expiration: ⤷  Try a Trial

Patent: 1811334
Estimated Expiration: ⤷  Try a Trial

Patent: 1902483
Estimated Expiration: ⤷  Try a Trial

Patent: 1906612
Estimated Expiration: ⤷  Try a Trial

Patent: 2211924
Estimated Expiration: ⤷  Try a Trial

Patent: 2315634
Estimated Expiration: ⤷  Try a Trial

Tunisia

Patent: 14000492
Estimated Expiration: ⤷  Try a Trial

Ukraine

Patent: 4421
Estimated Expiration: ⤷  Try a Trial

Patent: 6959
Estimated Expiration: ⤷  Try a Trial

Uruguay

Patent: 848
Estimated Expiration: ⤷  Try a Trial

Patent: 740
Estimated Expiration: ⤷  Try a Trial

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering IMBRUVICA around the world.

Country Patent Number Title Estimated Expiration
Brazil 112012030625 uso de inibidores de tirosina quinase de bruton (btk) ⤷  Try a Trial
Australia 2010201052 Inhibitors of Bruton's tyrosine kinase ⤷  Try a Trial
World Intellectual Property Organization (WIPO) 2016141068 ⤷  Try a Trial
Canada 2663116 INHIBITEURS DE LA TYROSINE KINASE DE BRUTON (INHIBITORS OF BRUTON'S TYROSINE KINASE) ⤷  Try a Trial
Japan 6937086 ⤷  Try a Trial
>Country >Patent Number >Title >Estimated Expiration

Supplementary Protection Certificates for IMBRUVICA

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2526934 132016000119245 Italy ⤷  Try a Trial PRODUCT NAME: IBRUTINIB O UN SUO SALE FARMACEUTICAMENTE ACCETTABILE PER IL TRATTAMENTO DI PAZIENTI ADULTI CON LEUCEMIA LINFOCITICA CRONICA (CLL) PRECEDENTEMENTE NON TRATTATA(IMBRUVICA); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/14/945, 20160530
2201840 2015/020 Ireland ⤷  Try a Trial PRODUCT NAME: IBRUTINIB, OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; REGISTRATION NO/DATE: EU/1/14/945 20141021
2201840 300728 Netherlands ⤷  Try a Trial DETAILS ASSIGNMENT: VERANDERING VAN EIGENAAR(S), SAMENVOEGEN
2529621 122017000015 Germany ⤷  Try a Trial PRODUCT NAME: IBRUTINIB ODER EIN PHARMAZEUTISCH ANNEHMBARES SALZ DAVON; REGISTRATION NO/DATE: EU/1/14/945-C(2015)4704 20150703
2201840 CR 2015 00021 Denmark ⤷  Try a Trial PRODUCT NAME: IBRUTINIB ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF; REG. NO/DATE: EU/1/14/945 20141023
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.